Jorge Plutzky, cardiologist perspective on RA at #ACR21 ⭐️CANTOS: Canakinumab for MACE shows ⬇️ inflammation, no change in LDL. Improvement in MACE events ▶️Plutzky: "Proof of concept study" @Rheumnow https://t.co/Xi9ZHxMtmu

Another benefit of DMARD use in RA. Dr Sood reports lower risk of long term opioid use. Very important given the harm of opioids Abstr#587 #ACR21 @RheumNow https://t.co/d1Dharf5jZ

We need to control not only inflammation but also lipids levels in our patients w/ IA! Dr Plutzky brilliantly talking us through CV risk and RA showing data on how poor LDL control and coronary microvascular dysfunction lead to worse long term CV outcomes. @RheumNow #ACR21 https://t.co/o6GWHDai5z

@MilenaGianfran @JYazdanyMD present on differential effects of biologics on CDAI in obese patients with rheumatoid arthritis. Abatacept better than TNFi in obese. Tocilizumab better than TNFi in non-obese. Abstr#0588 #ACR21 @RheumNow #ACRBest https://t.co/UcEpMAmNVw

Attaining low disease activity in #SLE ⬇️ mortality! More time in LLDAS = #lupus low disease activity state = ⬆️survival in >4000 pts with SLE. Also + was clinical remission on treatment CROT. Treat to a target has come to SLE @RheumNow #ACR21 abst0865 #ACRBest #RheumPix https://t.co/8ld8oncFRR

The drug retention for SEC and TNFi was similar in this RW study of 279 patients (TNFi 178, SEC 101).In subgroups analyses, age, BASDAI at diagnosis and BMI did not favour any group @RheumNow #ACR21 Abst#0911 https://t.co/g1tIy1qMX1 https://t.co/LHZMxMlzIB

Dr. P Crow #PhilipHench provides a tour of research on SLE pathogenesis: 👉discovery of Ab to small nuclear RNAs and the spliceosome 👉T cells' role on B cell differentiation 👉⬆️CD40L on SLE lymphocytes 👉IFN genes and their effects on the immune system #ACR21 @rheumnow https://t.co/6v9O19UUxX

No significant difference in effectiveness/treatment survival of different TNFi in axSpA Failure of 1st TNFi did not diminish effectiveness of a second TNFi Abs#938 #ACR21 @RheumNow https://t.co/SLrOV7wmvU https://t.co/fkpmseVwF6

#ACR21 #Abstr0686 A study used PET-CT to initially rule out cancer. Interestingly, they found ⬆️median muscle FDG uptake with PET-CT in IIM vs Non-IIM. Need further study on its added value compared to MRI/EMG @RheumNow https://t.co/F0B86ygjI9 https://t.co/eiJnqpU8ft

Dr. P Crow #PhilipHenchLecture IFN signature can parallel or predict flares #ACR21 @rheumnow https://t.co/OskxDuKPDH

Abstr 0579 Kim & Colleagues examined predictors of Tx change among RA patients w/ TNFi as 1st line biologic agent - Females & GC use more likely to switch agent - Vitamin D use & hx of other immune-mediated diseases (eg. Psoriasis, IBD) less likely to switch #ACR21 @RheumNow https://t.co/FM5mSWmSNA

@zach_wallace_md on RTX vs CYC remission induction in AAV. Multivariable and propensity score matching. No difference in ESRD or mortality. Real world confirmation of RAVE. Abstr#954 #ACR21 @RheumNow https://t.co/oSauqV8JnD